Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs.

OBJECTIVES: No large sample studies have been designed to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP1RAs) in the primary and secondary prevention of respiratory disorders. We aimed at evaluating the relationship between use of GLP1RAs and occurrence of 12 kinds of respiratory disorders. METHODS: Large randomized placebo-controlled trials of GLP1RAs were included. We conducted meta-analysis using random effects model and measured heterogeneity using I2 . Treatment effect was presented as risk ratio (RR) and 95% confidence interval (CI). RESULTS: Seven trials including 55 922 participants were included in meta-analysis. The occurrence rates of various respiratory disorders were low, with the minimum of 0.02% (pulmonary fibrosis) and the maximum of 2.31% (pneumonia). Although not reaching statistical significance, GLP1RAs versus placebo showed the reduced trends in the risks of nine kinds of respiratory disorders including pneumonia (RR 0.89, 95% CI 0.78-1.01), squamous cell carcinoma of lung (SCCL; RR 0.55, 95% CI 0.25-1.21), asthma (RR 0.82, 95% CI 0.51-1.32), and chronic obstructive pulmonary disease (COPD; RR 0.89, 95% CI 0.73-1.10), but the increased trend in interstitial lung disease (ILD; RR 1.89, 95% CI 0.87-4.08). GLP1RAs had neutral effects on two other respiratory disorders. Heterogeneity in any meta-analysis was absent or low. CONCLUSION: GLP1RAs show the reduced trends in the risks of nine kinds of respiratory disorders (eg, pneumonia, SCCL, asthma, and COPD), but the increased trend in the risk of ILD. However, these findings need to be validated by further studies due to the low incidence rates of all the respiratory disorders.

Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients.

BACKGROUND: Previous reports have demonstrated that S-1 has remarkable effects in the maintenance treatment of advanced non-small-cell lung cancer (NSCLC), and has less toxic and side effects than conventional drugs. AIM: To investigate the efficacy and safety of S-1 maintenance therapy in patients with advanced NSCLC. METHODS: Ninety-four patients with NSCLC admitted to our hospital from September 2015 to April 2018 were included in the study and divided into the S-1 group (47 cases) and the gemcitabine group (47 cases) by random digital table method. The S-1 group was treated with S-1, while the gemcitabine group received gemcitabine treatment. The clinical efficacy and quality of life of the patients after treatment in the two groups were evaluated. RESULTS: There was no significant difference in the total effectiveness rate between the two groups (P = 0.519). The quality-of-life scores indicated that there was no significant difference between the two groups in terms of four dimensions of the GQOLI-74 questionnaire (P = 0.518, 0.094, 0.338, 0.418). The incidence of nausea and vomiting, granulocytopenia and diarrhea in the S-1  group was significantly lower than that in the gemcitabine group (P = 0.001, 0.001 and 0.001, respectively). There was no significant difference in the incidence of thrombocytopenia (P = 0.366), the progression-free survival (P = 0.064), and the survival between the two groups (P = 0.050). CONCLUSION: S-1 maintenance therapy shows a significant therapeutic effect in patients with advanced NSCLC. It has the same clinical efficacy as gemcitabine, but with less toxic and side effects than conventional drugs.

[C2H4 reducing facility for controlled ecological life support system].

OBJECTIVE: To develop an experimental facility for reducing C2H4 produced by plants' growing in the controlled ecological life support system (CELSS). METHOD: Based on technical parameters and performance requirements, project planning, design drawing, fabrication, and debug were conducted. Then, an experimental test for reducing C2H4 was done by measuring the content of C2H4 in gases between the inlet and the outlet of the facility. Its C2H4 decomposing capacity was evaluated. RESULT: The facility worked well, and the parameters, such as energy consumption, and volume, met the design requirements. The experimental test results demonstrated that the content of C2H4 was reduced from 0.034 mg/kg to below 0.010 mg/kg, under the condition that the relative humidity and velocity of flow of the inlet-gas was 20% and 1.0-3.0 L/min respectively, and power of the lamp was 48 W. Considering the composition and the content of the gas in the outlet of the facility, there was no harmful product to the plants, except CO2 and H2O. CONCLUSION: The facility has reasonable technical indices, and smooth and dependable performances. It can be used as a facility for decomposing C2H4 in plants growing system in CELSS.

Characteristics of MnO2 catalytic ozonation of sulfosalicylic acid and propionic acid in water.

The characteristics of different types of MnO(2) catalytic ozonation of sulfosalicylic acid (SSal) and propionic acid (PPA) have been investigated in this paper. The experimental results show the dependence of catalytic activity of MnO(2) on organic compounds and the pH of solutions, but it is independent on the type of MnO(2). For example, three types of MnO(2) have not any catalytic activity when ozonation of PPA under the condition of this experiment. All MnO(2) catalytic ozonation of SSal at pH=1.0 have a greater total organic carbon removal than ozonation alone has, however, at pH=6.8 and 8.5, catalytic efficiency is not observed. Furthermore, the batch experimental results indicate that there are no direct relationship between the activity of metal oxide catalytic decomposition of ozone and that of its catalytic degradation of organic compounds.